Work

Kompleksnaya terapiya pri aterogennoydislipidemii i nealkogol'noy zhirovoybolezni pecheni

Year: 2011

Type: article

Abstract: Summary. Non-alcoholic fatty liver disease (NAFLD) is one of the major components of the metabolic syndrome. NAFLD is now recognized as one of the major cardiovascular risk factors since cholesterol synthesis takes place in the liver. In this connection, to choose hypolipidemic therapy that has well-known hepatotoxic effects is an intricate problem. Of great importance in the pathogenesis of NAFLD is the impaired colonic microflora and hence elevated levels of microbial waste products (short-chain fatty acids, endotoxin, nitric oxide), which should be also kept in mind when treating atherogenic dyslipidemia. Statin + probiotic combination therapy used in patients with NAFLD and atherogenic dyslipidemia is more effective than monotherapy in reducing the levels of cholesterol and intestinal microflora metabolism products.

Source: Cardiosomatics

DOI: 10.26442/cs44962

Authors: Elizaveta Andreevna Cherkashova, Larisa Arsent'evna Zvenigorodskaya, Natal'ya Gennad'evna Samsonova, Tamara Vasil'evna Nilova, Svetlana Yur'evna Sil'vestrova, Sergey Germanovich Khomeriki

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3123661689

FWCI:

Cites: 8

Cited by:

Related to: 10